The global active pharmaceutical ingredients (APIs) market was valued at USD 237.47 billion in 2023 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.75% from 2024 to 2030. Key factors driving this growth include advancements in API manufacturing, expansion of the biopharmaceutical sector, and an aging global population.

The API market is bolstered by the increasing prevalence of chronic diseases such as cardiovascular diseases and cancer. These conditions are expected to drive demand for pharmaceuticals, thereby boosting the API market. Supriya Lifescience Ltd. stands out as a leading manufacturer of APIs, focusing on therapeutic segments such as antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics.

Dr. Saloni Wagh, Director of Supriya Lifescience Ltd., shared insights on the company’s growth strategy and industry trends. She highlighted ambitious plans to double revenue to Rs 1,000 crore, leveraging higher-margin niche segments and expanding into contract manufacturing. The company aims to achieve sustainable growth rates and maintain strong EBITDA margins by FY25.

Supriya Lifescience Ltd. plans significant investments in capital expenditure over the next few years to support its expansion into new therapeutic areas and markets. With 80% of revenue coming from exports to 120 countries, including regulated markets in Latin America, North America, and Europe, the company aims to strengthen its presence in these regions. Future plans include entering additional countries and enhancing market penetration through innovative products and strategic partnerships.

Looking ahead, Supriya Lifescience Ltd. remains focused on growth through new product launches, market diversification, and capitalizing on contract manufacturing opportunities. The company’s robust expansion strategy underscores its commitment to becoming a key player in the global API market, catering to diverse therapeutic needs worldwide.